Eric Easom
Chief Executive Officer, Director at AN2 Therapeutics, Inc. (ANTX)
Eric Easom has filed 19 insider reports with the SEC since April 2022, as chief Executive Officer and director at AN2 Therapeutics, Inc. (ANTX). Eric Easom made no open-market purchases or sales in the last 12 months. The latest filing, on March 23, 2026, reports grant or award and sale back to the company at AN2 Therapeutics, Inc. (ANTX).
- Filings
- 19
- Companies
- 1
- Bought on market
- $114K
- Sold on market
- $1.55M
Companies where Eric Easom is an insider
| Company | Role | Shares held | Bought | Sold | Avg buy | Price now | Last filing |
|---|---|---|---|---|---|---|---|
| Chief Executive Officer, Director | 368,630 | $114K | $1.55M | $1.63 | $4.95+204% | Mar 23, 2026 |
Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record. Price now: the latest daily close, against the average buy price.
Every filing
- Mar 19, 2026ANTXSEC Form 4 filed by Easom EricForm 4Grant or awardSale back to the company
- Feb 20, 2026ANTXChief Executive Officer Easom Eric was granted 112,250 shares, increasing direct ownership by 44% to 368,630 unitsForm 4Grant or award
- Jun 2, 2025+$10.7KANTXChief Executive Officer Easom Eric bought $10,665 worth of shares (10,000 units at $1.07), increasing direct ownership by 4% to 256,380 unitsForm 4Open-market purchase
- Feb 26, 2025ANTXChief Executive Officer Easom Eric was granted 145,250 shares, increasing direct ownership by 144% to 246,380 unitsForm 4Grant or award
- Nov 18, 2024+$50KANTXChief Executive Officer Easom Eric bought $49,970 worth of shares (50,000 units at $1.00)Form 4Open-market purchase
- Mar 15, 2024ANTXEasom Eric was granted 99,000 shares, increasing direct ownership by 4,648% to 101,130 units (Amendment)Form 4Grant or award
- Mar 15, 2024ANTXEasom Eric was granted 99,000 shares, increasing direct ownership by 4,648% to 101,130 unitsForm 4Grant or award
- Jan 2, 2024-$55.8KANTXEasom Eric sold $55,802 worth of shares (2,777 units at $20.09), decreasing direct ownership by 57% to 2,130 unitsForm 4Open-market sale10b5-1 plan
- May 15, 2023+$53.8KANTXSEC Form 4 filed by Easom EricForm 4Open-market purchase
- Feb 23, 2023ANTXSEC Form 4 filed by Easom EricForm 4Grant or award
- Nov 14, 2022-$68KANTXSEC Form 4: Easom Eric sold $67,974 worth of shares (4,436 units at $15.32) as part of a pre-agreed trading plan, decreasing direct ownership by 47% to 4,907 unitsForm 4Open-market sale10b5-1 plan
- Nov 9, 2022-$268KANTXSEC Form 4: Easom Eric sold $267,794 worth of shares (17,166 units at $15.60) as part of a pre-agreed trading plan, decreasing direct ownership by 78% to 4,907 unitsForm 4Open-market sale10b5-1 plan
- Nov 7, 2022-$558KANTXSEC Form 4: Easom Eric sold $558,274 worth of shares (35,196 units at $15.86) as part of a pre-agreed trading plan, decreasing direct ownership by 88% to 4,907 unitsForm 4Open-market sale10b5-1 plan
- Nov 2, 2022-$64.6KANTXSEC Form 4: Easom Eric sold $64,625 worth of shares (4,232 units at $15.27) as part of a pre-agreed trading plan, decreasing direct ownership by 46% to 4,907 unitsForm 4Open-market sale10b5-1 plan
- Oct 28, 2022-$39.6KANTXSEC Form 4: Easom Eric sold $39,582 worth of shares (2,607 units at $15.18) as part of a pre-agreed trading plan, decreasing direct ownership by 35% to 4,907 unitsForm 4Open-market sale10b5-1 plan
- Oct 26, 2022-$147KANTXSEC Form 4: Easom Eric sold $147,358 worth of shares (9,350 units at $15.76) as part of a pre-agreed trading plan, decreasing direct ownership by 66% to 4,907 unitsForm 4Open-market sale10b5-1 plan
- Oct 21, 2022-$350KANTXSEC Form 4: Easom Eric sold $349,912 worth of shares (21,244 units at $16.47) as part of a pre-agreed trading plan, decreasing direct ownership by 81% to 4,907 unitsForm 4Open-market sale10b5-1 plan
- May 12, 2022ANTXSEC Form 4 filed by Easom EricForm 4Grant or award
- Mar 29, 2022ANTXSEC Form 4: Easom Eric converted options into 4,907 sharesForm 4Conversion of a derivative
Compare Eric Easom with
- Eric Easom vs Cameron C. Trenor III1 shared
- Eric Easom vs Robin Shane Readnour1 shared
- Eric Easom vs Margaret M FitzPatrick1 shared
- Eric Easom vs Joseph S Zakrzewski1 shared
- Eric Easom vs Kabeer Aziz1 shared
- Eric Easom vs Gilbert Lynn Marks1 shared
Other insiders at the same companies
- Cameron C. Trenor IIIANTX
- Robin Shane ReadnourANTX
- Margaret M FitzPatrickANTX
- Joseph S ZakrzewskiANTX
- Kabeer AzizANTX
- Gilbert Lynn MarksANTX
- Patricia A. MartinANTX
- Joshua M EizenANTX
- Sarah Joanne WilliamsANTX
- Lucy DayANTX
- Sanjay ChandaANTX
- Stephanie WongANTX
- Melvin K SpigelmanANTX
- Stephen David PriorANTX
- Braden Michael LeonardANTX
Questions about Eric Easom
- What is Eric Easom's role at AN2 Therapeutics, Inc.?
- Eric Easom reports to the SEC as chief Executive Officer and director at AN2 Therapeutics, Inc. (ANTX), according to the latest filing on March 23, 2026.
- How many shares does Eric Easom own?
- After the latest filing that states it, Eric Easom directly owned 368,630 shares of AN2 Therapeutics, Inc. (ANTX). Shares held through trusts, funds or family members are reported separately and are not counted here.
- Has Eric Easom bought or sold stock recently?
- The most recent open-market purchase was on June 2, 2025: bought 10,000 shares of AN2 Therapeutics, Inc. (ANTX) for $10.7K at an average of $1.07. The most recent open-market sale was on January 2, 2024: sold 2,777 shares of AN2 Therapeutics, Inc. (ANTX) for $55.8K at an average of $20.09.
- How do I get alerts when Eric Easom files?
- Follow Eric Easom on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.
From SEC Forms 3, 4, 5 and 144 filed by Eric Easom (SEC CIK 0001914503). Totals count each trade once, skipping amendments whose original is on file, from Apr 1, 2022 on. View on SEC EDGAR